HK Stock Market Move | FUSEN PHARM (01652) skyrocketed more than 410% once, and "Metformin Linagliptin (I)" was approved for listing.

FUSEN PHARM(01652) soared by over 410% at one point, rising 350% to 1.53 Hong Kong dollars, with a trading volume of 13.89 million Hong Kong dollars at the time of reporting. On the news front, FUSEN PHARM announced that the company's research and development of "Metformin Englitazone Tablets (I)" has received approval from the China National Medical Products Administration for listing. The approval is for the treatment of the following diseases: with dietary control and exercise, it is suitable for adult patients with type 2 diabetes who are currently receiving Englitazone and Metformin hydrochloride treatment, to improve their blood sugar control. The board believes that Metformin Englitazone Tablets (I) is another important product for the group, further enriching the group's product pipeline in the field of diabetes treatment. This product will provide more treatment options for a large number of diabetes patients.